Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Imaging experts debate link between CT scans, cancer risk

August 10, 2010
By Greg Frieherr
Greg Frieherr
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 19 No 8
Volume 19
Issue 8

Clinical studies examining the potential of CT exposure to cause cancer are under way, but it could be years or even a decade until the results are known, and even then, they may be inconclusive.

Clinical studies examining the potential of CT exposure to cause cancer are under way, but it could be years or even a decade until the results are known, and even then, they may be inconclusive.

A half dozen clinical studies are now enrolling hundreds of thousands of patients in Canada, the UK, Australia, Israel, Sweden, and France with the goal of looking specifically at whether CT is a cause of cancer. But the studies, mostly involving pediatric patients, will take many years to complete. And there is no guarantee the results will be definitive.

Andrew J. Einstein, MD, PhD, an assistant professor of clinical medicine in the departments of radiology and cardiology at New York's Columbia University, examined the current basis for concerns about radiation exposure from CT, noting that none of the data used to support these cautionary arguments involve CT radiation exposure itself. Instead they are largely drawn from studies examining survivors of the atomic bombing of Hiroshima, nuclear industry workers, and exposure of children to radiation in utero. "But it is still important that we do such studies because each additional study provides us with new information and a more complete picture of the issues that we are dealing with," Dr. Einstein said.


ANDREW J. EINSTEIN, MD, PHD

In the meantime, the CT community and the public will be left with only circumstantial data to make or break the connection between CT exams and cancer, a prospect that concerns Cynthia H. McCollough, PhD, director of the CT Clinical Innovation Center at the Mayo Clinic College of Medicine in Rochester, Minn.

Some patients are making poor decisions about their healthcare because of their unjustified fear of CT radiation, Dr. McCollough said, promulgated by data with considerable uncertainty. Despite 60 years of studying the A-bomb survivors, for example, no definitive conclusions have yet been made about the cancer risk at the relatively low doses commonly encountered during CT studies.

"When people say we just don't know what's happening, I disagree," she said. "We know that it is not a big effect. If it is an effect at all, it is a really small effect."

Dr. McCollough has a simple solution to the debate over radiation dose and CT, as it relates to deciding whether to schedule an exam. "If the CT is needed, do it, and do it carefully," she said. "And if it's not needed, don't do it."

References:

Source: 2010 International Symposium for Multidetector CT, International Society for Computed Tomography.

Articles in this issue

Colorectal cancer patients with vitamin D deficiency see worse outcomes
What is the Clinical Role of Induction Therapy in Locally Advanced Squamous Cell Cancer of the Head and Neck?
What is the Clinical Role of Induction Therapy in Locally Advanced Squamous Cell Cancer of the Head and Neck?
Who's News
Sonography better to monitor small testicular lesions
FDA Panel Says No More Avastin in Breast Cancer
Cell-signaling pathway may be new Rx target ER+ breast cancer
Evidence-based pathway plus electronic health records system matches major trials for colorectal cancer treatment outcomes
Ohio cancer center breaks ground on $1 billion addition
Second-Generation TKIs Poised to Succeed Imatinib in Newly Diagnosed CML
Imaging experts debate link between CT scans, cancer risk
From the ONI archives: CML patients’ molecular response to nilotinib continues to deepen over time
Smartphones hustle to maintain pace with rapid rate of change in oncology
Making comparative effectiveness work in cancer care
Geriatric assessment, communication skills essential for older patients
Patients look for answers on Web but trust it less
Recent Videos
Ongoing studies in kidney cancer aim to explore determinants of immune-related adverse effects and strategies for mitigating them.
Machine learning-based approaches may play a role in further understanding of how somatic alterations influence responses or resistance to therapy.
Data from a first-in-disease trial assessing a personalized cancer vaccine in RCC require validation at a larger level, according to David Braun, MD, PhD.
It can cause thrombocytopenia and diarrhea, which are generally manageable and not too big a deal.
2 KOLs are featured in this series.
Related Content
Advertisement

Understanding Palliative and End-Of-Life Care in Oncology

Understanding Palliative and End-Of-Life Care in Oncology

Julie M. Vose, MD, MBA
September 16th 2025
Article

Explore the vital role of palliative care in oncology, addressing misconceptions and enhancing patient support for better end-of-life experiences.


Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.

Unraveling Key Blood Cancer Takeaways From the 2025 SOHO Meeting

Francesca Palandri, MD, PhD;Sundar Jagannath, MD;Adam J. Olszewski, MD
September 15th 2025
Podcast

Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.


While the trial enrolled patients with renal cell carcinoma and ovarian cancer, the component of the trial including those with renal cell carcinoma was discontinued.

The FDA Grants BTD to R-DXd in Pretreated Gynecologic Cancers

Tim Cortese
September 15th 2025
Article

Findings from a phase 1 and the REJOICE-Ovarian01 trials supported the FDA’s decision to grant the designation to R-DXd in those with gynecologic cancers.


A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.

Elevating Community Oncology Care: Insights From World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Sam S. Chang MD, MBA;Jeff Yorio, MD
September 12th 2025
Podcast

A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.


Numerically higher ORRs were reported in those who received treatment in the second line vs third line, in those with a CTFI of 90 days or more, and those without CNS metastasis.

Lurbinectedin Yields Responses in Various ES-SCLC Subgroups

Tim Cortese
September 14th 2025
Article

Lurbinectedin achieved an ORR of 27% in all patients with extensive-stage small cell lung cancer in the phase 4 Jazz EMERGE 402 study.


Ateganosine plus cemiplimab was well tolerated in patients with heavily pretreated advanced NSCLC, with most adverse effects grades 1/2 in severity.

Ateganosine Combo Exhibits Favorable Efficacy vs SOC in Advanced NSCLC

Roman Fabbricatore
September 13th 2025
Article

Ateganosine plus cemiplimab was well tolerated in patients with heavily pretreated advanced NSCLC, with most adverse effects grades 1/2 in severity.

Related Content
Advertisement

Understanding Palliative and End-Of-Life Care in Oncology

Understanding Palliative and End-Of-Life Care in Oncology

Julie M. Vose, MD, MBA
September 16th 2025
Article

Explore the vital role of palliative care in oncology, addressing misconceptions and enhancing patient support for better end-of-life experiences.


Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.

Unraveling Key Blood Cancer Takeaways From the 2025 SOHO Meeting

Francesca Palandri, MD, PhD;Sundar Jagannath, MD;Adam J. Olszewski, MD
September 15th 2025
Podcast

Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.


While the trial enrolled patients with renal cell carcinoma and ovarian cancer, the component of the trial including those with renal cell carcinoma was discontinued.

The FDA Grants BTD to R-DXd in Pretreated Gynecologic Cancers

Tim Cortese
September 15th 2025
Article

Findings from a phase 1 and the REJOICE-Ovarian01 trials supported the FDA’s decision to grant the designation to R-DXd in those with gynecologic cancers.


A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.

Elevating Community Oncology Care: Insights From World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Sam S. Chang MD, MBA;Jeff Yorio, MD
September 12th 2025
Podcast

A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.


Numerically higher ORRs were reported in those who received treatment in the second line vs third line, in those with a CTFI of 90 days or more, and those without CNS metastasis.

Lurbinectedin Yields Responses in Various ES-SCLC Subgroups

Tim Cortese
September 14th 2025
Article

Lurbinectedin achieved an ORR of 27% in all patients with extensive-stage small cell lung cancer in the phase 4 Jazz EMERGE 402 study.


Ateganosine plus cemiplimab was well tolerated in patients with heavily pretreated advanced NSCLC, with most adverse effects grades 1/2 in severity.

Ateganosine Combo Exhibits Favorable Efficacy vs SOC in Advanced NSCLC

Roman Fabbricatore
September 13th 2025
Article

Ateganosine plus cemiplimab was well tolerated in patients with heavily pretreated advanced NSCLC, with most adverse effects grades 1/2 in severity.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.